Case report: Urgent liver pathologies: All in one

Pavlek, Goran; Romić, Ivan; Juzbasic, Kristina; Alduk, Ana Marija; Petrović, Igor; Radojkovic, Rudolf; Grbavac, Dario; Silovski, Hrvoje

doi:10.3389/fsurg.2022.940856

Cited by 2 publications

(2 citation statements)

References 29 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, HAIC may be beneficial since it decreases tumor size and by this, it reduces the risk of HCC rupture. 15 For patients with particular large tumors (>7 cm), the OS after TACE was only 11.2–13.2 months. 16 , 17 Therefore, patients with huge mass HCC and PVTT were included in the study and are reported in this report.…”

Section: Discussionmentioning

confidence: 99%

Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports

Tian,

Jin,

Sun

et al. 2023

JHC

View full text Add to dashboard Cite

Background Advanced-stage hepatocellular carcinoma (HCC), especially huge HCC or portal vein tumour thrombus (PVTT), is difficult to treat, and the prognosis is poor. The advantages of hepatic artery infusion chemotherapy (HAIC) combined with targeted therapy and immunotherapy for this complex disease are gradually becoming apparent. However, HAIC still has some inevitable disadvantages, such as arterial perfusion therapy requiring a long time, which results in many patients having difficulty completing the procedure. Modified HAIC (mHAIC)-based oxaliplatin and S-1 is a new treatment option for huge HCC or PVTT that can reduce complications and improve patient compliance. We report two cases of huge HCC or PVTT that were successfully treated with mHAIC combined with lenvatinib and camrelizumab. The clinical presentations, treatment strategies, and outcomes of these cases are presented. Case Presentation Case 1: A 52-year-old female was found to have a huge HCC with a size of 14×11 cm. She was treated with one cycle of mHAIC combined with transcatheter arterial chemoembolization (TACE), lenvatinib and camrelizumab and 3 cycles of mHAIC in combination with lenvatinib and camrelizumab. The patient’s follow-up maintenance therapy with lenvatinib and camrelizumab has been evaluated for efficacy in achieving complete response (CR). Case 2: A 57-year-old man was diagnosed with advanced HCC in combination with PVTT. He achieved partial remission (PR) after four cycles of mHAIC combined with lenvatinib and camrelizumab. This was followed by treatment with lenvatinib and camrelizumab with an efficacy assessment for CR, and progression-free survival (PFS) was 7 months. Conclusion For advanced HCC with a large mass or PVTT, mHAIC combined with lenvatinib and camrelizumab is a safe and effective treatment with good patient compliance.

show abstract

Section: Discussionmentioning

confidence: 99%

Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports

Tian,

Jin,

Sun

et al. 2023

JHC

View full text Add to dashboard Cite

show abstract

“…Hepatocellular carcinoma (HCC) accounts for 75%-85% of primary liver cancers (PLC) which is a common cancer worldwide with bad prognosis and maybe associated serious complications such as tumor rupture, and so on. It is the fourth leading cause of cancer-related deaths worldwide, and generally occurs in the context of chronic liver disease at the cirrhosis stage ( 1 , 2 ). Patients with HCC are usually diagnosed in advanced stages, with very limited therapeutic options and bleak outcomes.…”

Section: Introductionmentioning

confidence: 99%

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report

Wan,

Zhu

2023

Front. Oncol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a tumor with a high degree of malignancy. Patients have poor outcomes and short survival times, especially after progression to first-line systemic therapy. Regorafenib is the standard second-line treatment for HCC, but there is no conclusive evidence that regorafenib combined with immunotherapy can be used as a second-line treatment. We present the case of a 50-year-old man with a chronic hepatitis B (CHB) infection for more than 30 years who was diagnosed with stage Barcelona Clinic Liver Cancer (BCLC)-B hepatocellular carcinoma. Unfortunately, recurrence and metastasis occurred soon after radical surgery and standard first-line treatment with lenvatinib. The patient was then treated with regorafenib plus sintilimab as second-line treatment. Surprisingly, soon after treatment, the patient reached a state of partial response (PR) that lasted for more than one year, which is currently close to that of complete response (CR). Regorafenib combined with sintilimab as second-line treatment showed an excellent curative effect in this patient, who had HCC with multiple metastases to the liver and lungs. This treatment, which has tolerable side effects, enabled the patient to reach a state of PR that lasted over one year, which is currently close to CR. Therefore, it may be a potential second-line treatment strategy.

show abstract

Case report: Urgent liver pathologies: All in one

Cited by 2 publications

References 29 publications

Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports

Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report

Contact Info

Product

Resources

About